Search research articles
Contact Us
Filters
Showing results (141-150 of 184) with videos related to
Page
of 19
Sort By:
Future Oncology (London, England)
|
April 2, 2020
Quality of life with second or third line <i>nab</i>-paclitaxel-based regimens in advanced non-small-cell lung cancer
Santiago Ponce Aix, Denis Talbot, Ramaswamy Govindan, et al.
Lung Cancer (Auckland, N.Z.)
|
November 16, 2017
<i>nab</i>-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
Michael Thomas, David R Spigel, Robert M Jotte, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 12, 2019
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study
Daniel Morgensztern, Benjamin Besse, Laurent Greillier, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 26, 2019
An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer
Daniel Morgensztern, Nina Karaseva, Enriqueta Felip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 14, 2019
Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations
Siddhartha Devarakonda, Sumithra Sankararaman, Brett H Herzog, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2022
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer
D Ross Camidge, Fabrice Barlesi, Jonathan W Goldman, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 19, 2019
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer
David E Gerber, D Ross Camidge, Daniel Morgensztern, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2021
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma
D Ross Camidge, Daniel Morgensztern, Rebecca S Heist, et al.
JTO Clinical and Research Reports
|
January 10, 2022
A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC
D Ross Camidge, Fabrice Barlesi, Jonathan W Goldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 11, 2015
Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base
Cliff G Robinson, Aalok P Patel, Jeffrey D Bradley, et al.
Page
of 19
Search research articles
Search
Showing results (141-150 of 184) with videos related to
Sort By:
Page
of 19
Future Oncology (London, England)
|
April 2, 2020
Quality of life with second or third line <i>nab</i>-paclitaxel-based regimens in advanced non-small-cell lung cancer
Santiago Ponce Aix, Denis Talbot, Ramaswamy Govindan, et al.
Lung Cancer (Auckland, N.Z.)
|
November 16, 2017
<i>nab</i>-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
Michael Thomas, David R Spigel, Robert M Jotte, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 12, 2019
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study
Daniel Morgensztern, Benjamin Besse, Laurent Greillier, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 26, 2019
An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer
Daniel Morgensztern, Nina Karaseva, Enriqueta Felip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 14, 2019
Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations
Siddhartha Devarakonda, Sumithra Sankararaman, Brett H Herzog, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2022
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer
D Ross Camidge, Fabrice Barlesi, Jonathan W Goldman, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 19, 2019
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer
David E Gerber, D Ross Camidge, Daniel Morgensztern, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2021
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma
D Ross Camidge, Daniel Morgensztern, Rebecca S Heist, et al.
JTO Clinical and Research Reports
|
January 10, 2022
A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC
D Ross Camidge, Fabrice Barlesi, Jonathan W Goldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 11, 2015
Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base
Cliff G Robinson, Aalok P Patel, Jeffrey D Bradley, et al.
Page
of 19